



Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022)

- By Region- North America, Europe, APAC and RoW
- By Country - United States, Canada, United Kingdom, Germany, France, China, India, Japan
- Company Analysis



Table of Content

S.No	Particulars	Page No.
1.	Research Methodology	19
2.	Executive Summary	20
3.	Strategic Recommendation	21
3.1	Asia Pacific Region to witness fastest growth for HPV Treatment	22
3.2	Male segment is anticipated to witness highest growth	23
4.	HPV Vaccine Market: Product Outlook	24
5.	Global HPV Vaccine Market: Growth and Forecast	31
5.1	Global HPV Vaccine Market, By Value (2012-2016)	32
5.2	Global HPV Vaccine Market, By Value (2017-2022)	40
5.3	Global HPV Vaccine Market - By End-User, By Value	41
5.3.1	Global HPV Vaccine Market, By Value, % (2016)	41
5.3.2	Global HPV Vaccine Market, By Value, % (Forecast 2022F)	42

Table of Content

S.No	Particulars	Page No.
5.4	Global HPV Vaccine Market, By End-User, By Value (2012-2022)	43
5.4.1	Male, By Value (2012-2022)	43
5.4.2	Female, By Value (2012-2022)	43
5.5	Global HPV Vaccine Market, By Age-Group, By Value (2012-2022)	44
5.5.1	Adolescent, By Value (2012-2022)	44
5.5.2	Adult, By Value (2012-2022)	44
6.	North America HPV Vaccine Market: Growth and Forecast	46
6.1	North America HPV Vaccine Market, By Value (2012-2016)	47
6.2	North America HPV Vaccine Market, By Value (2017-2022)	50
6.3	North America HPV Vaccine Market - By End-User, By Value	51
6.3.1	North America HPV Vaccine Market, By Value, % (2016)	51
6.3.2	North America HPV Vaccine Market, By Value, % (Forecast 2022F)	52
6.4	North America HPV Vaccine Market, By End-User, By Value (2012-2022)	53
6.4.1	Male, By Value (2012-2022)	53
6.4.2	Female, By Value (2012-2022)	53

Table of Content

S. No	Particulars	Page No.
6.5	North America HPV Vaccine Market, By Age-Group, By Value (2012-2022)	54
6.5.1	Adolescent, By Value (2012-2022)	54
6.5.2	Adult, By Value (2012-2022)	54
6.6	North America HPV Vaccine Market: Country Analysis (U.S., Canada)	55
6.6.1	North America HPV Vaccine Market, Country Share, 2016 (% of Total)	55
6.6.2	North America HPV Vaccine Market, Country Share, 2022 (% of Total)	55
6.7	U.S. HPV Vaccine Market: Growth and Forecast	57
6.7.1	U.S. HPV Vaccine Market, By Value (2012-2016)	58
6.7.2	U.S. HPV Vaccine Market, By Value (2017-2022)	58
6.8	U.S. HPV Vaccine Market - By End-User, By Value	64
6.8.1	Male, By Value (2012-2022)	64
6.8.2	Female, By Value (2012-2022)	64
6.9	Canada HPV Vaccine Market: Growth and Forecast	66
6.9.1	Canada HPV Vaccine Market, By Value (2012-2016)	67
6.9.2	Canada HPV Vaccine Market, By Value (2017-2022)	67
6.10	Canada HPV Vaccine Market - By End-User, By Value	74
6.10.1	Male, By Value (2012-2022)	74
6.10.2	Female, By Value (2012-2022)	74

Table of Content

S.No	Particulars	Page No.
7.	Europe HPV Vaccine Market: Growth and Forecast	75
7.1	Europe HPV Vaccine Market, By Value (2012-2016)	76
7.2	Europe HPV Vaccine Market, By Value (2017-2022)	80
7.3	Europe HPV Vaccine Market - By End-User, By Value	81
7.3.1	Europe HPV Vaccine Market, By Value, % (2016)	81
7.3.2	Europe HPV Vaccine Market, By Value, % (Forecast 2022F)	82
7.4	Europe HPV Vaccine Market, By End-User, By Value (2012-2022)	83
7.4.1	Male, By Value (2012-2022)	83
7.4.2	Female, By Value (2012-2022)	83
7.5	Europe HPV Vaccine Market, By Age-Group, By Value (2012-2022)	84
7.5.1	Adolescent, By Value (2012-2022)	84
7.5.2	Adult, By Value (2012-2022)	84
7.6	Europe HPV Vaccine Market: Country Analysis (U.K., Germany, France & Rest of Europe)	85
7.6.1	Europe HPV Vaccine Market, Country Share, 2016 (% of Total)	85
7.6.2	Europe HPV Vaccine Market, Country Share, 2022 (% of Total)	85

Table of Content

S. No	Particulars	Page No.
7.7	U.K. HPV Vaccine Market: Growth and Forecast	88
7.7.1	U.K. HPV Vaccine Market, By Value (2012-2016)	89
7.7.2	U.K. HPV Vaccine Market, By Value (2017-2022)	89
7.8	U.K. HPV Vaccine Market - By End-User, By Value	94
7.8.1	Male, By Value (2012-2022)	94
7.8.2	Female, By Value (2012-2022)	94
7.9	Germany HPV Vaccine Market: Growth and Forecast	96
7.9.1	Germany HPV Vaccine Market, By Value (2012-2016)	97
7.9.2	Germany HPV Vaccine Market, By Value (2017-2022)	97
7.10	Germany HPV Vaccine Market - By End-User, By Value	104
7.10.1	Male, By Value (2012-2022)	104
7.10.2	Female, By Value (2012-2022)	104

Table of Content

S. No	Particulars	Page No.
7.11	France HPV Vaccine Market: Growth and Forecast	105
7.11.1	France HPV Vaccine Market, By Value (2012-2016)	105
7.11.2	France HPV Vaccine Market, By Value (2017-2022)	106
7.12	France HPV Vaccine Market - By End-User, By Value	111
7.12.1	Male, By Value (2012-2022)	111
7.12.2	Female, By Value (2012-2022)	111
7.13	Rest of Europe HPV Vaccine Market: Growth and Forecast	112
7.13.1	Rest of Europe HPV Vaccine Market, By Value (2012-2016)	112
7.13.2	Rest of Europe Vaccine Market, By Value (2017-2022)	112
8.	Asia-Pacific HPV Vaccine Market: Growth and Forecast	113
8.1	Asia-Pacific HPV Vaccine Market, By Value (2012-2016)	114
8.2	Asia-Pacific HPV Vaccine Market, By Value (2017-2022)	120
8.3	Asia-Pacific HPV Vaccine Market - By End-User, By Value	121
8.3.1	Asia-Pacific HPV Vaccine Market, By Value, % (2016)	121
8.3.2	Asia-Pacific HPV Vaccine Market, By Value, % (Forecast 2022F)	122

Table of Content

S.No	Particulars	Page No.
8.4	Asia-Pacific HPV Vaccine Market, By End-User, By Value (2012-2022)	123
8.4.1	Male, By Value (2012-2022)	123
8.4.2	Female, By Value (2012-2022)	123
8.5	Asia-Pacific HPV Vaccine Market, By Age-Group, By Value (2012-2022)	124
8.5.1	Adolescent, By Value (2012-2022)	124
8.5.2	Adult, By Value (2012-2022)	124
8.6	Asia-Pacific HPV Vaccine Market: Country Analysis (Japan, China, India)	125
8.6.1	Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total)	125
8.6.2	Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total)	125
8.7	Japan HPV Vaccine Market: Growth and Forecast	127
8.7.1	Japan HPV Vaccine Market, By Value (2012-2016)	128
8.7.2	Japan HPV Vaccine Market, By Value (2017-2022)	128
8.8	Japan HPV Vaccine Market - By End-User, By Value	131
8.8.1	Male, By Value (2012-2022)	11
8.8.2	Female, By Value (2012-2022)	131

Table of Content

S. No	Particulars	Page No.
8.9	China HPV Vaccine Market: Growth and Forecast	132
8.9.1	China HPV Vaccine Market, By Value (2012-2016)	133
8.9.2	China HPV Vaccine Market, By Value (2017-2022)	133
8.10	China HPV Vaccine Market - By End-User, By Value	139
8.10.1	Male, By Value (2012-2022)	139
8.10.2	Female, By Value (2012-2022)	139
8.11	India HPV Vaccine Market: Growth and Forecast	140
8.11.1	India HPV Vaccine Market, By Value (2012-2016)	141
8.11.2	India HPV Vaccine Market, By Value (2017-2022)	141
8.12	India HPV Vaccine Market - By End-User, By Value	147
8.12.1	Male, By Value (2012-2022)	147
8.12.2	Female, By Value (2012-2022)	147
9.	ROW HPV Vaccine Market: Growth and Forecast	148
9.1	ROW HPV Vaccine Market, By Value (2012-2016)	149
9.2	ROW HPV Vaccine Market, By Value (2017-2022)	150

Table of Content

S. No	Particulars	Page No.
10.	Market Dynamics	153
10.1	Increasing healthcare awareness about Sexually Transmissible Disease	155
10.2	Development of Healthcare Infrastructure	156
10.3	Rising global healthcare expenditure and favorable reimbursed policies	157
11.	Market Restraints	158
12.	Market Trends	160
13.	SWOT Analysis – HPV Vaccine Market	163
14.	Porter’s Five Forces Analysis	165
15.	Policy and Regulatory Landscape	167
16.	Company Profile	177
16.1	Merck and Co	178
16.2	GlaxoSmithKline	181
17.	About Us	184

List of Figures

Figure No.	Figure Title	Page No.
Figure 1:	Global HPV vaccine Market Size, By Value, 2012-2016 (USD Million)	32
Figure 2:	World Male Population Estimates, 2017 (In Millions)	33
Figure 3:	World Female Population Estimates, 2017 (In Millions)	33
Figure 4:	World Female Population, Age 10-14 Years Old (2012-2016)	34
Figure 5:	World Male Population, Age 10-14 Years Old (2012-2016)	34
Figure 6:	Global Healthcare Expenditure, 2012-2016 (In Trillion)	36
Figure 7:	Top 10 Most Frequent Cancer in Females, World, (Age-standardised incidence rate per 100,000 women)	37
Figure 8:	Top 10 Most Frequent Cancer Deaths in Females, World, (Age-standardised incidence rate per 100,000 women)	37
Figure 9:	Age-Standardized Cervical Cancer Incidence Rate (per 100,000 women per year), By Region	37
Figure 10:	HPV Related Cancer Cases in Women/ Year, 530,000	38
Figure 11:	HPV Related Cancer Cases in Men/ Year, 39,000	38
Figure 12:	Global HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)	40
Figure 13:	Global HPV vaccine Market Size, By End-User, 2016 (%)	41
Figure 14:	Global HPV Vaccine Market Size, By End-User, 2022 (%)	42
Figure 15:	Global HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)	43
Figure 16:	Global HPV Vaccine Market – By Age Group, By Value 2012-2022 (USD Million)	44
Figure 17:	North America HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)	47
Figure 18:	North America GDP, 2012-2015 (USD Trillion)	48
Figure 19:	North America GDP, By Select Country, 2016 (USD Trillion)	48

List of Figures

Figure No.	Figure Title	Page No.
Figure 20:	North America Healthcare Cost Per Capita, By Select Country, 2016 (USD)	48
Figure 21:	North America Female Population, Age 10-14 Years Old (2012-2016)	49
Figure 22:	North America Male Population, Age 10-14 Years Old (2012-2016)	49
Figure 23:	North America HPV Vaccine Market Size, By Value, 2017-2022(USD Million)	50
Figure 24:	North America HPV vaccine Market Size, By End-User , 2016 (%)	51
Figure 25:	North America HPV Vaccine Market Size, By End-User, 2022 (%)	52
Figure 26:	North America HPV Vaccine Market, End-User, By Value 2012-2022 (USD Million)	53
Figure 27:	North America HPV Vaccine Market, By Age Group, By Value 2012-2022 (USD Million)	54
Figure 28:	North America HPV Vaccine Market, Country Share, 2016 (% of Total)	55
Figure 29:	North America HPV Vaccine Market, Country Share, 2022 (% of Total)	55
Figure 30:	U.S. HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)	58
Figure 31:	U.S. Female Population, Age 10-14 Years Old (2012-2016)	61
Figure 32:	U.S. Male Population, Age 10-14 Years Old (2012-2016)	61
Figure 33:	U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD)	61
Figure 34:	U.S. HPV vaccine Market Size, By End-User, 2016 (%)	62
Figure 35:	U.S. HPV Vaccine Market Size, By End-User, 2022 (%)	63
Figure 36:	U.S. HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)	64
Figure 37:	Annual Sales of Cervarix vaccines in U.S., (In Million USD) 2012-2016	65
Figure 38:	Canada HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)	67
Figure 39:	Canada Female Population, Age 10-14 Years Old (2012-2016)	68

List of Figures

Figure No.	Figure Title	Page No.
Figure 40:	Canada Male Population, Age 10-14 Years Old (2012-2016)	68
Figure 41:	Normal Cytology	70
Figure 42:	Low-Grade lesions	70
Figure 43:	High-Grade lesions	70
Figure 44:	Cervical Cancer	70
Figure 45:	Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)	71
Figure 46:	Canada HPV vaccine Market Size, By End-User, 2016 (%)	72
Figure 47:	Canada HPV Vaccine Market Size, By End-User, 2022 (%)	73
Figure 48:	Canada HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)	74
Figure 49:	Europe HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)	76
Figure 50:	Europe, Female Population aged 15+, By Region, 2017 (In Millions)	77
Figure 51:	European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)	77
Figure 52:	Europe Female Population, Age 10-14 Years Old (2012-2016)	77
Figure 53:	Europe Male Population, Age 10-14 Years Old (2012-2016)	77
Figure 54:	Europe, GDP, By Select Country, 2016 (USD Billion)	78
Figure 55:	Europe Health Spending Per Capita, By Select Country, 2016 (USD)	78
Figure 56:	Europe HPV Vaccine Market Size, By Value, Forecast, 2017-2022 (USD Million)	80
Figure 57:	Europe HPV Vaccine Market Size, By End-User, 2016 (%)	81
Figure 58:	Europe HPV Vaccine Market Size, By End-User, 2022 (%)	82
Figure 59:	Europe HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)	83
Figure 60:	Europe HPV Vaccine Market – By Age Group, By Value 2012-2022 (USD Million)	84

List of Figures

Figure No.	Figure Title	Page No.
Figure 61:	Europe HPV Vaccine Market, Country Share, 2016 (% of Total)	85
Figure 62:	Europe HPV Vaccine Market, Country Share, 2022 (% of Total)	85
Figure 63:	Annual Sales of Cervarix vaccines in Europe, (In Million USD) 2012-2016	86
Figure 64:	U.K. HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)	89
Figure 65:	U.K. Female Population, Age 10-14 Years Old (2012-2016)	91
Figure 66:	U.K. Male Population, Age 10-14 Years Old (2012-2016)	91
Figure 67:	Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)	91
Figure 68:	U.K., Per Capita Healthcare Expenditure, 2012-2016 (In USD)	91
Figure 69:	U.K. HPV Vaccine Market Size, By End User, 2016 (%)	92
Figure 70:	U.K. HPV Vaccine Market Size, By End User, 2022 (%)	93
Figure 71:	U.K. HPV Vaccine Market - End-User, By Value 2012-2022 (USD Million)	94
Figure 72:	Germany HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)	97
Figure 73:	Germany Female Population, Age 10-14 Years Old (2012-2016)	98
Figure 74:	Germany Male Population, Age 10-14 Years Old (2012-2016)	98
Figure 75:	Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)	98
Figure 76:	Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)	99
Figure 77:	Germany HPV Vaccine Market Size, By End User, 2016 (%)	102
Figure 78:	Germany HPV Vaccine Market Size, By End User, 2022 (%)	103
Figure 79:	Germany HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)	104
Figure 80:	France HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)	106

List of Figures

Figure No.	Figure Title	Page No.
Figure 81:	Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)	107
Figure 82:	France Female Population, Age 10-14 Years Old (2012-2016)	108
Figure 83:	France Male Population, Age 10-14 Years Old (2012-2016)	108
Figure 84:	France Per Capita Healthcare Expenditure, 2012-2014 (In USD)	108
Figure 85:	France HPV Vaccine Market Size, By End-User, 2016 (%)	109
Figure 86:	France HPV Vaccine Market Size, By End-User, 2022 (%)	110
Figure 87:	France HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)	111
Figure 88:	Rest of Europe HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)	112
Figure 89:	Asia-Pacific HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)	114
Figure 90:	Asia Female Population, Age 10-14 Years Old (2012-2016)	118
Figure 91:	Asia Male Population, Age 10-14 Years Old (2012-2016)	118
Figure 92:	APAC, GDP, By Select Country, 2016 (USD Billion)	119
Figure 93:	APAC Health Expenditure Per Capita, Public and Private, By Select Country, 2016 (USD)	119
Figure 94:	Asia-Pacific HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)	120
Figure 95:	Asia-Pacific HPV Vaccine Market Size, By End-User, 2016 (%)	121
Figure 96:	Asia-Pacific HPV Vaccine Market Size, By End-User, 2022 (%)	122
Figure 97:	Asia-pacific HPV Vaccine - End-User, By Value 2012-2022 (USD Million)	123
Figure 98:	Asia-Pacific HPV Vaccine Market – Age Group, By Value 2012-2022 (USD Million)	124
Figure 99:	Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total)	125
Figure 100:	Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total)	125

List of Figures

Figure No.	Figure Title	Page No.
Figure 101:	Japan HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)	128
Figure 102:	Japan HPV Vaccine Market Size, By End-User, 2016 (%)	129
Figure 103:	Japan HPV Vaccine Market Size, By End-User, 2022 (%)	130
Figure 104:	Japan HPV Vaccine - End-User, By Value 2012-2022 (USD Million)	131
Figure 105:	China HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)	133
Figure 106:	Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)	135
Figure 107:	China Female Population, Age 10-14 Years Old (2012-2016)	136
Figure 108:	China Male Population, Age 10-14 Years Old (2012-2016)	136
Figure 109:	China Per Capita Healthcare Expenditure, 2012-2014 (In USD)	136
Figure 110:	China HPV Vaccine Market Size, By End-User, 2016 (%)	137
Figure 111:	China HPV Vaccine Market Size, By End-User, 2022 (%)	138
Figure 112:	China HPV Vaccine - By End-User, By Value 2012-2022 (USD Million)	139
Figure 113:	India HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)	141
Figure 114:	India Female Population, Age 10-14 Years Old (2012-2016)	143
Figure 115:	India Male Population, Age 10-14 Years Old (2012-2016)	143
Figure 116:	Prevalence of Cervical Cancer among female (Patients per 100,000) (2012-2016)	143
Figure 117:	India HPV Vaccine Market Size, By End-User, 2016 (%)	144
Figure 118:	India HPV Vaccine Market Size, By End-User, 2022 (%)	145
Figure 119:	India HPV Vaccine - By End-User, By Value 2012-2022 (USD Million)	146
Figure 120:	Rest of Asia-Pacific HPV Vaccine Market Size, By Value, 2012-2022 (USD Million)	147

List of Figures

Figure No.	Figure Title	Page No.
Figure 121:	ROW HPV Vaccine Market Size, By Value, 2012-2016 (USD Million)	149
Figure 122:	ROW HPV Vaccine Market Size, By Value, 2017-2022 (USD Million)	150
Figure 123:	Africa Female Population, Age 10-14 Years Old (2012-2016)	151
Figure 124:	Africa Male Population, Age 10-14 Years Old (2012-2016)	151
Figure 125:	Prevalence of Cervical Cancer, among women in Africa (Patients per 100,000 (2012-2016)	151
Figure 126:	Prevalence of Cervical Cancer among female in Brazil (Patients per 100,000 (2012-2016)	152
Figure 127:	Global Healthcare Expenditure, 2012-2016 (In Trillion)	157
Figure 128:	Annual Sales of HPV vaccines, By leading players, (In Million USD) 2012-2016	175
Figure 129:	Market Share of Leading players in HPV vaccine market, 2016	176
Figure 130:	Merck & Co., Net Sales, 2012-2016 (In million USD)	179
Figure 131:	Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD)	179
Figure 132:	Merck & Co., Net Sales, By Geographic Location, % Share 2016	179
Figure 133:	Merck & Co., Net Revenue, By Business Segment, % Share 2016	179
Figure 134:	GlaxoSmithKline Annual Revenue, 2014-2016 (USD Million)	182
Figure 135:	Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015 - 2016 (USD Million)	182
Figure 136:	GlaxoSmithKline Sales, By Region, 2016 (%)	182
Figure 137:	GlaxoSmithKline, Sales, By Segment 2016 (%)	182

List of Tables

Table No.	Table Title	Page No.
Table A:	Globally approved HPV vaccines, 2016	29
Table B:	HPV Vaccine Market Segmentation Flowchart	30
Table C:	Estimated number of HPV Associated cases in 2017	59
Table D:	Estimated new HPV related cancers cases, 2011, 2012 & 2016	69
Table E:	Newly registered diagnosed cases of HPV related cancer in England, 2016	90
Table F:	Estimated and Predicted HPV related cancer among male and female, 2011, 2012 & 2016	100
Table G:	Estimated and Predicted HPV related cancer among female, 2011, 2012 & 2016	100
Table H:	Key Statistics on HPV burden in Asia	114
Table I:	Estimated HPV related New Cancer Cases and Deaths (Thousands), By Sex, 2015	135

Research Methodology

For our study on Global HPV Vaccine Market, we have conducted comprehensive secondary research followed by an extensive primary research. In the process of secondary research, we have scrutinized industry documents, accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and our internal knowledge base. In the process of primary research, we have interviewed various industry experts across the value chain of HPV Vaccine Market.

Market size of the actual period (2012-2016) has been evaluated on the basis of growth trends of the industry in the last five years, and confirming the findings through primary research. Annual reports of the companies are scanned to further validate the market size and to estimate the size of various other end-user sectors. Market sizing and growth in the forecast period (2017-2022) is estimated through product mapping, application in end-user industries, growth of allied sectors and historical growth pattern of the industry. All the relevant data points/ statistics in the forecast period are validated through relevant and reliable primary sources.

Report Focus: HPV Vaccine Market

-By Region- North America, Europe, APAC and ROW

-By Country - United States, Canada, United Kingdom, Germany, France, China, India, Japan


Company Analysis

Companies Contacted: GlaxoSmithKline Pharmaceuticals Ltd

Global HPV Vaccine Market Overview

Rising Prevalence of Sexually Transmissible Diseases, increasing global adolescence population, growing healthcare burden due to Sexually Transmissible virus propelled the market growth

Figure : Global HPV vaccine Market Size, By Value, 2012-2016 (USD Million)




Source: Azoth Analytics Estimates

- A Xxxxx
- A Xxxxx
- A Xxxxx
- A Xxxxx
- A Xxxxx
- A Xxxxx

Global HPV Vaccine Market - By Age Group, By Value

Figure : Global HPV Vaccine Market – By Age Group, By Value 2012-2022 (USD Million)




Source: Azoth Analytics Estimates

- A Xxxxx
- A Xxxxx
- A Xxxxx
- A Xxxxx
- A Xxxxx
- A xxxxx

North America HPV Vaccine Market - By End-User, By Value

Higher healthcare burden due to Cervical Cancer caused by HPV virus is attributed to the larger market share in female segment

Figure : North America HPV vaccine Market Size, By End-User , 2016 (%)



Source: Azoth Analytics Estimates

Key Drivers

Xxxxx
xxxxx

Xxxxx
xxxxx

Xxxxx
xxxxx


Xxxxx
xxxxx

Germany HPV Vaccine Market - By End-User, By Value

Figure : Germany HPV Vaccine Market - By End-User, By Value 2012-2022 (USD Million)

CAGR 2012-2016
Male: xx%; Female: xx%

CAGR 2017-2022
Male: xx%; Female: xx%




Source: Azoth Analytics Estimates

- A Xxxxx
- A Xxxxx
- A Xxxxx
- A Xxxxx
- A xxxxx


Asia-Pacific HPV Vaccine Market - By Country Share

Figure : Asia-Pacific HPV Vaccine Market, Country Share, 2016 (% of Total)



Source: Azoth Analytics Estimates

Figure : Asia-Pacific HPV Vaccine Market, Country Share, 2022 (% of Total)



Source: Azoth Analytics Estimates

About Azoth Analytics Pvt Ltd.

Azoth Analytics is a business research and analytics firm that creates in-depth research res and provides customized research solutions and consultancy services. Verticals in which Azoth Analytics specializes include healthcare and Pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research res by recording, interpreting and analyzing information. Strategic market sizing and data dredging End Users include secondary research, and primary research (interviews with management personnel and industry experts).

Disclaimer: *Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or User.. Also, analysis provided in the re are meant for customers' internal use only and not for general publication or disclosure to third parties.*
